Pentacyclic triterpenoid compound as well as preparation method and application thereof
Through the reaction of pentacyclic triterpene raw materials and organic diacid monomethyl ester chloride, combined with silica gel column chromatography technology, methylmalonyl oleanium alkyl triterpene compounds were successfully prepared, solving the synthesis method in the prior art The deficiency has achieved significant inhibitory activity on COX-2 and is suitable for the development of anti-inflammatory drugs and cosmetics.
Patent Information
- Application Number
- CN202410443644.1
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-04-13
- Publication Date
- 2024-11-08
- Estimated Expiration
- 2044-04-13
AI Technical Summary
The existing technology lacks cost-effective synthesis methods of methylmalonyl oleanium triterpene compounds and their analogs, and no literature has been reported in the research on its anti-inflammatory activity, which is difficult to meet the needs of bioactivity research and pharmaceutical cosmetics fields. .
By reacting pentacyclic triterpene raw materials with organic diacid monomethyl ester chloride in organic amine medium, combined with silica gel column chromatography technology, methylmalonyl oleanium alkyl triterpene compounds were prepared and applied to anti-inflammatory Drugs and cosmetics development.
Achieved the efficient synthesis of methylmalonyl oleanium triterpene compounds, showing significant inhibitory activity against cyclooxygenase-2 (COX-2), suitable for the preparation of anti-inflammatory drugs and cosmetics, and provides a Efficient and fast synthesis method.
Smart Images

Figure BDA0004790133400000021 
Figure BDA0004790133400000122 
Figure BDA0004790133400000131
Abstract
Description
Technical Field
[0001] The present invention relates to the field of medical technology, and in particular to a pentacyclic triterpenoid compound and a preparation method and application thereof. Background Art
[0002] Cynomorium songaricum is a parasitic plant belonging to the family Cynomorium. It parasitizes on the roots of Nitraria tangutorum. It is also known as immortal medicine, ground hairball, rusty iron rod, and lock-jaw. Its rhizome can be used as medicine to replenish yin and protect yang, promote metabolism, enhance immune function, and delay aging. Its efficacy has been recorded in writing as early as the pre-Qin period. It was used as medicine in the Han Dynasty and was treasured by famous doctors and famous cases of successive dynasties. "Compendium of Materia Medica" records that "it is sweet, warm, and non-toxic. It greatly replenishes yin, benefits essence and blood, and facilitates bowel movements. It moisturizes and nourishes tendons, and treats weakness." "Compendium of Materia Medica Congxin" records that "it replenishes essence and invigorates yang, moisturizes and nourishes tendons, treats weakness, and eliminates large intestine." "Zhongyao Zhi" records that "it nourishes the kidney, moistens the intestine, and strengthens the waist and knees. It mainly treats male impotence, female infertility, blood deficiency and constipation, and waist and knee weakness." Modern medical research shows that it has an effect on aging symptoms from mild memory impairment to dementia, mainly by protecting neuroblastoma cells from Aβ or superoxide anion-induced hippocampal neurogenesis damage and changing brain-derived neurotrophic factor (BDNF) and serum corticosterone levels. The active substances in it mainly include triterpenes, steroids, lignins and flavonoids, especially the natural product methylmalonyloleanane-type triterpenoid compounds, which have significant activity in anti-oxidation, anti-virus and treatment of neurological diseases. However, due to its low content and difficulty in separation and extraction, a large amount of this compound can only be obtained through chemical synthesis methods to meet the needs of subsequent biological activity research.
[0003] At present, there is no literature reporting the synthesis and anti-inflammatory activity of natural product methylmalonyloleanane triterpenoids and their analogs. Therefore, it is of great significance to develop an economical and efficient method for synthesizing natural product methylmalonyloleanane triterpenoids and their analogs and to use them in the pharmaceutical and cosmetic fields for their anti-inflammatory activity. Summary of the invention
[0004] The purpose of the present invention is to overcome the shortcomings of the prior art and provide a pentacyclic triterpenoid compound and a preparation method and application thereof.
[0005] To achieve the above object, the technical solution adopted by the present invention is:
[0006] In the first aspect, the present invention provides a pentacyclic triterpenoid compound, the structural formula of which is as follows:
[0007]
[0008] Among them, -R 1 It is an organic diacid monomethyl ester acyl group, -R 2 -CH3 or -H, -R 3 -CH 3 or -H.
[0009] As a preferred embodiment of the present invention, the organic diacid monomethyl ester acyl group includes any one of malonic acid monomethyl ester acyl group, succinic acid monomethyl ester acyl group, fumaric acid monomethyl ester acyl group, maleic acid monomethyl ester acyl group, glutaric acid monomethyl ester acyl group, adipic acid monomethyl ester acyl group, suberic acid monomethyl ester acyl group, azelaic acid monomethyl ester acyl group, sebacic acid monomethyl ester acyl group, and dodecanedioic acid monomethyl ester acyl group.
[0010] In a second aspect, the present invention provides a method for preparing the pentacyclic triterpenoid compound as described in the first aspect, comprising the following steps:
[0011] S1. In the presence of an organic solvent, a pentacyclic triterpene raw material and an organic diacid monomethyl ester chloride are stirred and reacted under the action of an organic amine to obtain a crude reaction product;
[0012] S2, distilling the crude reaction product obtained in step S1 under reduced pressure to remove the organic solvent to obtain a concentrate;
[0013] The pentacyclic triterpenoid raw material includes at least one of oleanolic acid and ursolic acid;
[0014] S2. The concentrate obtained in step S2 is subjected to silica gel column chromatography to obtain the pentacyclic triterpenoid compound.
[0015] As a preferred embodiment of the present invention, the molar ratio of the organic diacid monomethyl ester chloride to the pentacyclic triterpenoid raw material is (1-2):1.
[0016] As a preferred embodiment of the present invention, the organic diacid monomethyl chloride includes any one of malonic acid monomethyl chloride, succinic acid monomethyl chloride, fumaric acid monomethyl chloride, maleic acid monomethyl chloride, glutaric acid monomethyl chloride, adipic acid monomethyl chloride, suberic acid monomethyl chloride, azelaic acid monomethyl chloride, sebacic acid monomethyl chloride and dodecanedioic acid monomethyl chloride.
[0017] As a preferred embodiment of the present invention, step S1 specifically comprises: dissolving an organic diacid monomethyl ester in an organic solvent at 0-5°C, then sequentially adding 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride and 1-hydroxybenzotriazole, and reacting with stirring for 20-40 minutes to obtain a reaction mixture containing an organic diacid monomethyl ester chloride; adding a pentacyclic triterpene raw material and an organic amine to the reaction mixture containing an organic diacid monomethyl ester chloride at 0-5°C, and continuing to react with stirring for 3-8 hours to obtain a crude reaction product;
[0018] The organic diacid monomethyl ester includes any one of monomethyl malonate, monomethyl succinate, monomethyl fumarate, monomethyl maleate, monomethyl glutarate, monomethyl adipate, monomethyl suberate, monomethyl azelaic acid, monomethyl sebacate, and monomethyl dodecanedioate;
[0019] The molar ratio of the 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride to the organic diacid monomethyl ester is (1-1.2):1; the molar ratio of the 1-hydroxybenzotriazole to the organic diacid monomethyl ester is (1-1.2):1.
[0020] It is understandable that the temperature of step S1 is controlled at 0-5°C to avoid excessively high temperature causing the reaction product to be unstable or even decompose.
[0021] As a preferred embodiment of the present invention, step S1 specifically comprises: dissolving the pentacyclic triterpene raw material in an organic solvent at 0-5°C, adding an organic amine and an organic diacid monomethyl chloride in sequence, keeping warm and stirring for 20-40 minutes, heating to 16-26°C and keeping warm and stirring for 1-5 hours to obtain a crude reaction product.
[0022] As a preferred embodiment of the present invention, the organic amine includes at least one of triethylamine, diethylamine, trimethylamine, dimethylamine and tetramethylamine.
[0023] As a preferred embodiment of the present invention, the volume ratio of the organic amine to the mass ratio of the pentacyclic triterpenoid raw material is (2-5):10.
[0024] As a preferred embodiment of the present invention, the organic solvent is at least one of N,N-dimethylformamide and dichloromethane.
[0025] As a preferred embodiment of the present invention, the volume ratio of the organic solvent to the mass ratio of the pentacyclic triterpenoid raw material is (8-10) mL: 1 g.
[0026] In a third aspect, the present invention provides a use of the pentacyclic triterpenoid compound as described in the first aspect in the preparation of anti-inflammatory drugs.
[0027] As a preferred embodiment of the present invention, the dosage form of the anti-inflammatory drug includes tablets, granules, and capsules.
[0028] As a preferred embodiment of the present invention, the anti-inflammatory drug includes the pentacyclic triterpenoid compound and a pharmaceutically acceptable carrier.
[0029] Furthermore, the pharmaceutically acceptable carrier includes at least one of a diluent, a disintegrant, a binder, a lubricant, and a stabilizer.
[0030] In a fourth aspect, the present invention provides a use of the pentacyclic triterpenoid compound as described in the first aspect in the preparation of anti-inflammatory cosmetics.
[0031] Compared with the prior art, the present invention has the following beneficial effects:
[0032] (1) The pentacyclic triterpenoid compounds provided by the present invention belong to methylmalonyloleanane-type triterpenoid compounds and analogs, which show good inhibitory activity against cyclooxygenase-2 (COX-2) and can be used to prepare anti-inflammatory drugs;
[0033] (2) The present invention uses oleanolic acid or ursolic acid as a matrix, and reacts with an organic diacid monomethyl ester or an organic diacid monomethyl ester chloride under the action of a condensing agent, thereby introducing a specific organic diacid monomethyl ester acyl group into the 3-hydroxyl group of the matrix. The reaction conditions are mild, the synthesis speed is fast, and the yield is high. The present invention provides an efficient and quick method for methylmalonyloleanane-type triterpene compounds and analogs. DETAILED DESCRIPTION
[0034] In order to better illustrate the purpose, technical solutions and advantages of the present invention, the present invention will be further described below in conjunction with specific embodiments.
[0035] Unless otherwise specified, other materials, reagents, etc. used in the following examples and application examples can be obtained from commercial sources.
[0036] Unless otherwise specified, the methods used in the following embodiments and application examples are conventional methods in the art.
[0037] Examples 1-20
[0038] The embodiment of the pentacyclic triterpenoid compound of the present invention, the preparation method of the pentacyclic triterpenoid compound comprises the following steps:
[0039] S1. At 0°C, the reactant B was dissolved in 100 mL of dry anhydrous N,N-dimethylformamide, 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride and 1-hydroxybenzotriazole were added in sequence at 0°C, and the mixture was stirred at 0°C for 30 min. Then, 10 g of the reactant A and 3 mL of triethylamine were added, and the mixture was stirred at 0°C for 8 h to obtain a crude reaction product;
[0040] The molar ratio of reactant A to reactant B is 1:1;
[0041] The molar ratio of 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride to reactant B is 1.1:1;
[0042] The molar ratio of 1-hydroxybenzotriazole to reactant B is 1.1:1;
[0043] S2. After the reaction is completed by thin layer detection, the crude reaction product obtained in step S1 is evaporated under reduced pressure to remove the organic solvent, 50 mL of ethyl acetate and 50 mL of deionized water are added for extraction to obtain an organic phase, the organic phase is dried over anhydrous sodium sulfate, filtered and concentrated to obtain a concentrate; reactant A and reactant B are shown in Table 1.
[0044] S3. The concentrate obtained in step S2 is subjected to silica gel column chromatography to obtain the pentacyclic triterpenoid compound, and the yield thereof is shown in Table 1, wherein the yield = (theoretical yield of the compound - actual yield of the compound) / theoretical yield of the compound.
[0045] The pentacyclic triterpenoid compounds obtained in the above Examples 1-20 were subjected to nuclear magnetic resonance detection.
[0046] The structural characterization data of the compound obtained in Example 1 are:
[0047] 1 H NMR (400 MHz, CDCl 3 )δ5.21(t,J=3.6Hz,1H,H-12),3.67(s,3H,H-4'),4.48(dd,J=10.4,5.9Hz,1H,H-3),3.30(s,2H,H-2'),2.75(d d,J=13.8,4.6Hz,1H,H-18),1.91(td,J=13.7,3.9Hz,2H,H-16),1.05,0.87,0.86,0.84,0.82,0.76,0.70(each s,each3H,CH 3 ×7);
[0048] 13 CNMR (100MHz, CDCl 3 )δ181.7(C-28),166.1(C-3'),165.1(C-1'),142.6(C-13),121.5(C-12),81.4(C-3),54.3,51.4(C-4'),46.5,4 5.6,44.9,40.6(C-2'),40.1,38.3,37.1,36.8,36.0,32.8,31.4,26.6,24.9,22.6,22.4,17.1,16.0,15.5,14.3;
[0049] MS (ESI) m / z: [M+H] + Theoretical value 557.38, [M+H] + The measured value is 557.35.
[0050] The structural characterization data of the compound obtained in Example 2 are:
[0051] 1 H NMR (400 MHz, CDCl 3 )δ5.23(t,J=3.7Hz,1H,H-12),3.66(s,3H,H-5'),4.48(dd,J=10.1,5.7Hz,1H,H-3),2.77(dd,J=13.7,4.6Hz,1H,H-18),2.73( m,2H,H-3'),2.63(m,2H,H-2'),1.93(td,J=13.9,3.7Hz,2H,H-16),1.03,0.89,0.85,0.83,0.82,0.76,0.69(eachs,each3H,CH 3 ×7);
[0052] 13 CNMR (100MHz, CDCl 3 )δ181.6(C-28),166.3(C-4'),165.2(C-1'),142.3(C-13),121.2(C-12),81.5(C-3),54.5,51.3(C-5'),46.5,45.6,44 .8,40.1,39.7,38.3,37.1,36.8,36.0,32.8,31.4,29.3(C-2'),26.6(C-3'),24.7,22.7,22.3,17.3,16.1,15.5,14.1;
[0053] MS (ESI) m / z: [M+H] + Theoretical value 571.39, [M+H] + The measured value is 571.41.
[0054] The structural characterization data of the compound obtained in Example 3 are:
[0055] 1 HNMR (400MHz, CDCl 3 )δ6.33(d,J=12.4Hz,2H,H-2',H-3'),5.25(t,J=3.7Hz,1H,H-12),3.69(s,3H,H-5'),4.43(dd,J=9.9,5.5Hz,1H,H-3),2.79( dd,J=13.5,4.7Hz,1H,H-18),1.91(td,J=13.7,3.6Hz,2H,H-16),1.03,0.89,0.88,0.85,0.82,0.77,0.69(eachs,each3H,CH 3 ×7);
[0056] 13 CNMR (100MHz, CDCl 3 )δ181.3(C-28),167.3(C-4'),166.2(C-1'),142.5(C-13),133.9(C-3'),130.7(C-2'),121.3(C-12),81.3(C-3),54.6, 51.1(C-5'),46.5,45.6,44.8,40.3,39.6,38.3,37.5,36.8,36.0,32.9,31.4,24.3,22.8,22.3,17.5,16.3,15.5,14.3;
[0057] MS (ESI) m / z: [M+H] + Theoretical value 569.38, [M+H] + The measured value is 569.35.
[0058] The structural characterization data of the compound obtained in Example 4 are:
[0059] 1 HNMR (400MHz, CDCl 3 )δ6.47(d,J=3.9Hz,2H,H-2',H-3'),5.24(t,J=3.6Hz,1H,H-12),3.73(s,3H,H-5'),4.45(dd,J=10.3,5.7Hz,1H,H-3),2.77( dd,J=13.7,4.6Hz,1H,H-18),1.90(td,J=13.7,3.6Hz,2H,H-16),1.01,0.88,0.87,0.83,0.82,0.77,0.71(eachs,each3H,CH 3 ×7);
[0060] 13 CNMR (100MHz, CDCl 3 )δ181.1(C-28),167.3(C-4'),166.4(C-1'),142.5(C-13),133.6(C-3'),130.8(C-2'),121.7(C-12),81.7(C-3),54.6, 51.9(C-5'),46.8,45.6,44.3,40.3,39.7,38.3,37.6,36.8,36.1,32.9,31.1,24.3,22.7,22.5,17.5,16.5,15.5,14.0;
[0061] MS (ESI) m / z: [M+H]+ Theoretical value 569.38, [M+H] + The measured value is 569.40.
[0062] The structural characterization data of the compound obtained in Example 5 are:
[0063] 1 H NMR (400 MHz, CDCl 3 )δ5.24(t,J=3.7Hz,1H,H-12),3.69(s,3H,H-6'),4.45(dd,J=10.7,5.4Hz,1H,H-3),2.79(dd,J=13.3,4.7Hz,1H,H-18),2.36(m,2H,H-4 '),2.34(m,2H,H-2'),2.29(m,2H,H-3'),1.96(td,J=13.3,3.9Hz,2H,H-16),1.01,0.89,0.85,0.83,0.81,0.76,0.68(eachs,each3H,CH 3 ×7);
[0064] 13 CNMR (100MHz, CDCl 3 )δ181.6(C-28),167.3(C-5'),167.0(C-1'),142.3(C-13),121.2(C-12),81.5(C-3),54.6,51.7(C-6'),46.5,45.6,45.0,40 .1,39.7,38.4,37.1,36.6,36.1,33.3(C-4'),32.8,31.4,29.7(C-2'),24.7,22.7,22.3,20.3(C-3'),17.3,16.5,15.3,14.1;
[0065] MS (ESI) m / z: [M+H] + Theoretical value 585.41, [M+H] + The measured value is 585.46.
[0066] The structural characterization data of the compound obtained in Example 6 are:
[0067] 1 H NMR (400 MHz, CDCl 3)δ5.23(t,J=3.7Hz,1H,H-12),3.63(s,3H,H-7'),4.46(dd,J=10.4,5.5Hz,1H,H-3),2.71(dd,J=13.7,4.7Hz,1H,H-18),2.37(m,2H,H-2'), 2.33(m,2H,H-5'),1.96(td,J=13.3,3.9Hz,2H,H-16),1.68(m,4H,H-3',H-4'),1.02,0.90,0.83,0.82,0.80,0.79,0.69(eachs,each3H,CH 3 ×7);
[0068] 13 CNMR (100MHz, CDCl 3 )δ181.3(C-28),171.3(C-6'),170.1(C-1'),142.1(C-13),121.3(C-12),81.5(C-3),54.9,51.9(C-7'),46.9,45.6,45.2,41.3,39. 9,38.5,37.3,36.6,36.2,33.9(C-2'),33.3(C-5'),32.8,31.4,24.7,24.3(C-3'),24.1(C-4'),22.8,22.3,17.3,16.5,15.1,14.3;
[0069] MS (ESI) m / z: [M+H] + Theoretical value 599.43, [M+H] + The measured value is 599.41.
[0070] The structural characterization data of the compound obtained in Example 7 are:
[0071] 1 H NMR (400 MHz, CDCl 3)δ5.24(t,J=3.8Hz,1H,H-12),3.63(s,3H,H-9'),4.41(dd,J=10.5,5.4Hz, 1H,H-3),2.73(dd,J=13.7,4.3Hz,1H,H-18),2.36(m,2H,H-2'),2.32(m,2H, H-7'),1.96(td,J=13.3,3.9Hz,2H,H-16),1.66(m,4H,H-3',H-6'),1.63(m, 4H,H-4',H-5'),1.03,0.93,0.82,0.81,0.80,0.77,0.70(eachs,each3H,CH 3 ×7);
[0072] 13 CNMR (100MHz, CDCl 3 )δ181.3(C-28),172.9(C-8'),172.2(C-1'),142.3(C-13),121.2(C-12) ,81.5(C-3),54.7,51.9(C-9'),46.8,45.6,45.1,41.6,39.7,38.3,37.5 ,36.7,36.1,34.2(C-2'),33.6(C-7'),32.8,31.4,28.7(C-4'),28.5(C- 5'),25.1(C-3'),25.0(C-6'),24.7,22.8,22.1,17.3,16.5,15.5,14.3;
[0073] MS (ESI) m / z: [M+H] + Theoretical value 627.46, [M+H] + The measured value is 627.49.
[0074] The structural characterization data of the compound obtained in Example 8 are:
[0075] 1 HNMR (400MHz, CDCl 3)δ5.21(t,J=3.6Hz,1H,H-12),3.61(s,3H,H-10'),4.43(dd,J=10.3,5.4Hz,1 H,H-3),2.76(dd,J=13.3,4.1Hz,1H,H-18),2.35(m,2H,H-2'),2.32(m,2H,H- 8'),1.96(td,J=13.3,3.9Hz,2H,H-16),1.66(m,4H,H-3',H-7'),1.33(m,4H, H-4',H-6'),1.26(m,2H,H-5'),1.02,0.95,0.84,0.81,0.79,0.76,0.69(each s,each3H,CH 3 ×7);
[0076] 13 CNMR (100MHz, CDCl 3 )δ181.5(C-28),173.0(C-9'),172.8(C-1'),142.3(C-13),121.1(C-12),81 .5(C-3),54.9,51.9(C-10'),46.8,45.7,45.1,41.6,39.6,38.3,37.5,36.7 ,36.3,34.2(C-2'),33.6(C-8'),32.7,31.4,29.3(C-4'),29.1(C-5'),29.0 (C-6'),25.1(C-3'),25.0(C-7'),24.7,22.8,22.1,17.1,16.5,15.3,14.1;
[0077] MS (ESI) m / z: [M+H] + Theoretical value 641.47, [M+H] + The measured value is 641.43.
[0078] The structural characterization data of the compound obtained in Example 9 are:
[0079] 1 HNMR (400MHz, CDCl 3)δ5.21(t,J=3.7Hz,1H,H-12),3.62(s,3H,H-11'),4.42(dd,J=10.3,5.4Hz,1H ,H-3),2.77(dd,J=13.5,4.3Hz,1H,H-18),2.35(m,2H,H-2'),2.31(m,2H,H-9') ,1.97(td,J=13.3,3.9Hz,2H,H-16),1.69(m,4H,H-3',H-8'),1.37(m,4H,H-4' ,H-7'),1.28(m,4H,H-5',H-6'),1.03,0.93,0.87,0.81,0.79,0.77,0.68(each s,each3H,CH 3 ×7);
[0080] 13 CNMR (100MHz, CDCl 3 )δ181.5(C-28),173.2(C-10'),173.0(C-1'),142.5(C-13),121.1(C-12),81.5 (C-3),54.8,51.9(C-11'),46.9,45.7,45.3,41.6,39.7,38.3,37.3,36.7,36.1 ,34.5(C-2'),33.7(C-9'),32.7,31.4,29.4(C-4'),29.3(C-5'),29.1(C-6'),2 9.0(C-7'),25.1(C-3'),25.0(C-8'),24.6,22.9,22.1,17.3,16.5,15.3,14.0;
[0081] MS (ESI) m / z: [M+H] + Theoretical value 655.49, [M+H] + The measured value is 655.51.
[0082] The structural characterization data of the compound obtained in Example 10 are:
[0083] 1 HNMR (400MHz, CDCl 3)δ5.19(t,J=3.6Hz,1H,H-12),3.61(s,3H,H-13'),4.41(dd,J=10.4,5.5Hz,1H,H-3),2.7 9(dd,J=13.5,4.3Hz,1H,H-18),2.35(m,2H,H-2'),2.32(m,2H,H-11'),1.96(td,J=13.6, 3.9Hz,2H,H-16),1.67(m,4H,H-3',H-10'),1.34(m,4H,H-4',H-9'),1.31(m,4H,H-6',H- 7'),1.28(m,4H,H-5',H-8'),1.01,0.95,0.87,0.83,0.79,0.76,0.69(eachs,each3H,CH 3 ×7);
[0084] 13 CNMR (100MHz, CDCl 3 )δ180.9(C-28),173.1(C-12'),173.0(C-1'),142.1(C-13),121.4(C-12),81.3(C-3), 54.9,51.9(C-13'),46.8,45.7,45.5,41.6,39.9,38.3,37.5,36.7,36.1,34.3(C-2'), 33.7(C-11'),32.7,31.4,29.7(C-6'),29.4(C-7'),29.2(C-5'),29.0(C-8'),29.0(C- 4'),28.7(C-9'),25.3(C-3'),25.0(C-10'),24.6,22.9,22.5,17.3,16.1,15.3,14.3;
[0085] MS (ESI) m / z: [M+H] + Theoretical value 683.52, [M+H] + The measured value is 683.51.
[0086] The structural characterization data of the compound obtained in Example 11 are:
[0087] 1 HNMR (400MHz, CDCl 3)δ5.21(t,J=3.6Hz,1H,H-12),3.67(s,3H,H-4'),4.48(dd,J=10.4,5.9Hz,1H,H-3),3.30(s,2H,H- 2'),2.75(dd,J=13.8,4.6Hz,1H,H-18),1.91(td,J=13.7,3.9Hz,2H,H-16),0.95(d,J=6.4Hz,3H,CH 3 ),0.86(d,J=6.4Hz,3H,CH 3 ),1.05,0.84,0.82,0.76,0.70(eachs,each3H,CH 3 ×5);
[0088] 13 CNMR (100MHz, CDCl 3 )δ181.7(C-28),166.1(C-3'),165.1(C-1'),142.6(C-13),121.5(C-12),81.4(C-3),54.3,51.4(C-4'),46.5,4 5.6,44.9,40.6(C-2'),40.1,38.3,37.1,36.8,36.0,32.8,31.4,26.6,24.9,22.6,22.4,17.1,16.0,15.5,14.3;
[0089] MS (ESI) m / z: [M+H] + Theoretical value 557.38, [M+H] + The measured value is 557.35.
[0090] The structural characterization data of the compound obtained in Example 12 are:
[0091] 1 HNMR (400MHz, CDCl 3 )δ5.21(t,J=3.6Hz,1H,H-12),3.69(s,3H,H-5'),4.48(dd,J=10.1,5.5Hz,1H,H-3),2.77(dd,J=13.7,4.7Hz ,1H,H-18),2.75(m,2H,H-3'),2.63(m,2H,H-2'),1.95(td,J=13.9,3.7Hz,2H,H-16),0.96(d,J=6.4Hz,3H,CH 3 ),0.86(d,J=6.4Hz,3H,CH 3),1.03,0.89,0.82,0.73,0.70(eachs,each3H,CH 3 ×5);
[0092] 13 CNMR (100MHz, CDCl 3 )δ181.3(C-28),166.3(C-4'),165.0(C-1'),142.3(C-13),121.4(C-12),81.5(C-3),54.5,51.5(C-5'),46.5,45.6,44 .6,40.1,39.8,38.3,37.1,36.9,36.0,32.8,31.5,29.3(C-2'),26.7(C-3'),24.7,22.6,22.3,17.3,16.3,15.5,14.0;
[0093] MS (ESI) m / z: [M+H] + Theoretical value 571.39, [M+H] + The measured value is 571.33.
[0094] The structural characterization data of the compound obtained in Example 13 are:
[0095] 1 HNMR (400MHz, CDCl 3 )δ6.35(d,J=12.4Hz,2H,H-2',H-3'),5.22(t,J=3.6Hz,1H,H-12),3.67(s,3H,H-5'),4.43(dd,J=9.9,5.5H z,1H,H-3),2.79(dd,J=13.5,4.7Hz,1H,H-18),1.96(td,J=13.6,3.6Hz,2H,H-16),0.95(d,J=6.4Hz,3H,CH 3 ),0.87(d,J=6.4Hz,3H,CH 3 ),1.03,0.87,0.81,0.76,0.69(eachs,each3H,CH 3 ×5);
[0096] 13 CNMR (100MHz, CDCl 3)δ181.1(C-28),167.7(C-4'),166.6(C-1'),142.5(C-13),133.9(C-3'),130.7(C-2'),121.3(C-12),81.6(C-3),54.6, 51.4(C-5'),46.5,45.7,44.8,40.3,39.6,38.6,37.5,36.8,36.4,32.9,31.5,24.3,22.8,22.4,17.5,16.3,15.6,14.3;
[0097] MS (ESI) m / z: [M+H] + Theoretical value 569.38, [M+H] + The measured value is 569.41.
[0098] The structural characterization data of the compound obtained in Example 14 are:
[0099] 1 HNMR (400MHz, CDCl 3 )δ6.51(d,J=3.8Hz,2H,H-2',H-3'),5.24(t,J=3.6Hz,1H,H-12),3.73(s,3H,H-5'),4.43(dd,J=10.3,5.7H z,1H,H-3),2.77(dd,J=13.7,4.6Hz,1H,H-18),1.93(td,J=13.7,3.6Hz,2H,H-16),0.95(d,J=6.5Hz,3H,CH 3 ),0.86(d,J=6.5Hz,3H,CH 3 ),1.06,0.90,0.83,0.73,0.70(eachs,each3H,CH 3 ×5);
[0100] 13 CNMR (100MHz, CDCl 3 )δ181.3(C-28),167.6(C-4'),166.7(C-1'),142.5(C-13),133.9(C-3'),130.7(C-2'),121.7(C-12),81.7(C-3),54.6, 51.6(C-5'),46.8,45.7,44.3,40.3,39.7,38.3,37.6,36.8,36.1,32.9,31.3,24.3,22.7,22.5,17.5,16.5,15.5,14.1;
[0101] MS (ESI) m / z: [M+H] + Theoretical value 569.38, [M+H] + The measured value is 569.41.
[0102] The structural characterization data of the compound obtained in Example 15 are:
[0103] 1 HNMR (400MHz, CDCl 3 )δ5.21(t,J=3.7Hz,1H,H-12),3.67(s,3H,H-6'),4.45(dd,J=10.7,5.4Hz,1H,H-3),2.79(dd,J=13.3,4.7Hz,1H,H-18),2.39(m,2H, H-4'),2.35(m,2H,H-2'),2.29(m,2H,H-3'),1.96(td,J=13.3,3.9Hz,2H,H-16),0.97(d,J=6.4Hz,3H,CH3),0.85(d,J=6.4Hz,3H,CH 3 ),1.05,0.88,0.80,0.75,0.71(each s,each 3H,CH 3 ×5);
[0104] 13 CNMR (100MHz, CDCl 3 )δ181.3(C-28),168.0(C-5'),167.3(C-1'),142.3(C-13),121.2(C-12),81.5(C-3),54.6,51.6(C-6'),46.5,45.7,45.0,40 .1,39.7,38.3,37.1,36.6,36.1,33.5(C-4'),32.8,31.4,29.7(C-2'),24.6,22.7,22.3,20.1(C-3'),17.3,16.5,15.3,14.1;
[0105] MS (ESI) m / z: [M+H] + Theoretical value 585.41, [M+H] + The measured value is 585.38.
[0106] The structural characterization data of the compound obtained in Example 16 are:
[0107] 1 HNMR (400MHz, CDCl 3)δ5.23(t,J=3.6Hz,1H,H-12),3.63(s,3H,H-7'),4.44(dd,J=10.4,5.5Hz,1H,H-3),2.76(dd,J=13.7,4.5Hz,1H,H-18),2 .37(m,2H,H-2'),2.32(m,2H,H-5'),1.97(td,J=13.5,3.9Hz,2H,H-16),1.67(m,4H,H-3',H-4'),0.95(d,J=6.6Hz,3H,CH 3 ),0.89(d,J=6.5Hz,3H,CH 3 ),1.02,0.87,0.82,0.79,0.75(each s,each3H,CH 3 ×5);
[0108] 13 CNMR (100MHz, CDCl 3 )δ181.3(C-28),171.3(C-6'),170.1(C-1'),142.1(C-13),121.3(C-12),81.6(C-3),54.9,51.8(C-7'),46.9,45.6,45.2,41.3,39. 9,38.5,37.3,36.6,36.2,33.9(C-2'),33.3(C-5'),32.8,31.4,24.7,24.2(C-3'),24.1(C-4'),22.7,22.3,17.3,16.5,15.1,14.3;
[0109] MS (ESI) m / z: [M+H] + Theoretical value 599.43, [M+H] + The measured value is 599.45.
[0110] The structural characterization data of the compound obtained in Example 17 are:
[0111] 1 H NMR (400 MHz, CDCl 3)δ5.23(t,J=3.6Hz,1H,H-12),3.63(H3s,3H,H-9'),4.40(dd,J=10.5,5.4Hz,1H,H-3),2.71(dd,J=13.4,4.3Hz,1H,H-18),2.39(m,2H, H-2'),2.32(m,2H,H-7'),1.94(td,J=13.3,3.9Hz,2H,H-16),1.68(m,4H,H-3',H-6'),1.64(m,4H,H-4',H-5'),0.93(d,J=6.4Hz,3H,CH 3 ),0.87(d,J=6.5Hz,3H,C),1.04,0.91,0.88,0.79,0.76(eachs,each3H,CH 3 ×5);
[0112] 13 CNMR (100MHz, CDCl 3 )δ181.2(C-28),172.8(C-8'),172.3(C-1'),142.3(C-13),121.1(C-12) ,81.1(C-3),54.9,51.9(C-9'),46.7,45.6,45.1,41.6,39.7,38.3,37.5 ,36.7,36.2,34.2(C-2'),33.7(C-7'),32.8,31.4,28.7(C-4'),28.5(C- 5'),25.0(C-3'),24.7(C-6'),24.5,22.8,22.1,17.3,16.5,15.5,14.1;
[0113] MS (ESI) m / z: [M+H] + Theoretical value 627.46, [M+H] + The measured value is 627.43.
[0114] The structural characterization data of the compound obtained in Example 18 are:
[0115] 1 HNMR (400MHz, CDCl 3)δ5.24(t,J=3.6Hz,1H,H-12),3.63(s,3H,H-10'),4.43(dd,J=10.3,5.4Hz,1H,H-3),2.77(dd,J=13.3,4.3Hz,1H,H-18),2.38(m,2H,H-2'),2.3 0(m,2H,H-8'),1.97(td,J=13.3,4.1Hz,2H,H-16),1.68(m,4H,H-3',H- 7'),1.33(m,4H,H-4',H-6'),1.27(m,2H,H-5'),0.96(d,J=6.4Hz,3H,CH 3 ),0.85(d,J=6.4Hz,3H,CH 3 ),1.02,0.88,0.86,0.79,0.76(eachs,each3H,CH 3 ×5);
[0116] 13 CNMR (100MHz, CDCl 3 )δ181.4(C-28),173.1(C-9'),172.8(C-1'),142.3(C-13),121.1(C-12),81 .7(C-3),54.6,51.9(C-10'),46.9,45.7,45.4,41.6,39.8,38.3,37.6,36.7 ,36.1,34.0(C-2'),33.7(C-8'),32.7,31.4,29.3(C-4'),29.1(C-5'),28.8 (C-6'),25.1(C-3'),24.9(C-7'),24.7,22.8,22.2,17.3,16.5,15.2,14.3;
[0117] MS (ESI) m / z: [M+H] + Theoretical value 641.47, [M+H] + The measured value is 641.49.
[0118] The structural characterization data of the compound obtained in Example 19 are:
[0119] 1 HNMR (400MHz, CDCl 3)δ5.20(t,J=3.6Hz,1H,H-12),3.62(s,3H,H-11'),4.41(dd,J=10.3,5.5 Hz,1H,H-3),2.78(dd,J=13.7,4.4Hz,1H,H-18),2.33(m,2H,H-2'),2.30( m,2H,H-9'),1.97(td,J=13.3,3.9Hz,2H,H-16),1.67(m,4H,H-3',H-8'), 1.33(m,4H,H-4',H-7'),1.28(m,4H,H-5',H-6'),0.97(d,J=6.5Hz,3H,CH 3 ),0.87(d,J=6.5Hz,3H,CH 3 ),1.05,0.87,0.82,0.77,0.71(eachs,each3H,CH 3 ×5);
[0120] 13 CNMR (100MHz, CDCl 3 )δ181.3(C-28),173.0(C-10'),172.7(C-1'),142.5(C-13),121.3(C-12),81.5 (C-3),54.9,51.9(C-11'),46.8,45.7,45.4,41.6,39.8,38.3,37.6,36.7,36.0 ,34.6(C-2'),33.7(C-9'),32.7,31.5,29.5(C-4'),29.1(C-5'),29.0(C-6'),2 8.8(C-7'),25.1(C-3'),24.9(C-8'),24.7,22.9,22.3,17.3,16.1,15.3,14.1;
[0121] MS (ESI) m / z: [M+H] + Theoretical value 655.49, [M+H] + The actual measured value is 655.50.
[0122] The structural characterization data of the compound obtained in Example 20 are:
[0123] 1 HNMR (400MHz, CDCl 3)δ5.21(t,J=3.7Hz,1H,H-12),3.62(s,3H,H-13'),4.44(dd,J=10.1,5.3Hz,1H, H-3),2.81(dd,J=13.7,4.3Hz,1H,H-18),2.35(m,2H,H-2'),2.31(m,2H,H-11'), 1.99(td,J=13.6,3.8Hz,2H,H-16),1.66(m,4H,H-3',H-10'),1.34(m,4H,H-4', H-9'),1.32(m,4H,H-6',H-7'),1.29(m,4H,H-5',H-8'),0.97(d,J=6.6Hz,3H,CH 3 ),0.83(d,J=6.4Hz,3H,CH 3 ),1.06,0.86,0.82,0.78,0.73(each s,each 3H,CH 3 ×5);
[0124] 13 CNMR (100MHz, CDCl 3 )δ181.3(C-28),173.2(C-12'),173.0(C-1'),142.3(C-13),121.4(C-12),81.6(C-3), 54.9,51.7(C-13'),46.8,45.9,45.5,41.7,39.9,38.5,37.5,36.9,36.1,34.5(C-2'), 33.6(C-11'),32.7,31.5,29.6(C-6'),29.4(C-7'),29.1(C-5'),29.0(C-8'),28.9(C- 4'),28.7(C-9'),25.5(C-3'),25.1(C-10'),24.6,22.6,22.5,17.4,16.1,15.3,14.1;
[0125] MS (ESI) m / z: [M+H] + Theoretical value 683.52, [M+H] + The measured value is 683.54.
[0126] From the above results, it can be seen that Examples 1-20 successfully prepared the following pentacyclic triterpenoid compounds:
[0127] Among them, -R 1 , -R 2 and-R 3 As shown in Table 1.
[0128] Table 1
[0129]
[0130]
[0131] Effect Example 1
[0132] In order to verify the efficacy of the pentacyclic triterpenoid compounds of the present invention, the compounds obtained in Examples 1-20 were used as test samples, and indomethacin and resveratrol were used as control samples to conduct the following tests:
[0133] (1) Dissolve the sample in ethyl acetate and dilute it to a concentration of 1 μM with reaction buffer; the volume ratio of ethyl acetate to reaction buffer is 2:1;
[0134] (2) preparing a reaction mixture, the reaction mixture comprising 950 mL of reaction buffer, 10 mL of COX-2, and 10 mL of heme;
[0135] (3) Test group: 1 mL of the sample obtained in step (1) and 1.15 mL of the reaction mixture obtained in step (2) were added to the 100% initial activity tube and incubated in a 37°C water bath for 15 minutes; 20 μL of the reaction buffer was added to the 100% initial activity tube;
[0136] Control group: inactive COX-2 (10 mL) and reaction buffer (20 mL) were added to the background tube;
[0137] Each group was stimulated by adding arachidonic acid (10 mL) and continued to rotate and culture for 2 minutes, and the reaction was terminated by adding 50 mL of 1 M hydrochloric acid solution and 100 mL of saturated stannous chloride solution in sequence;
[0138] (4) Quantification of prostaglandins was performed using an ELISA method (COX-2 inhibitor screening kit: 96 assays, Cayman). The reaction contents were diluted 10-fold with reaction buffer and transferred to a 96-well microplate coated with mouse anti-rabbit IgG. Then, 1 mL of prostaglandin screening AchE tracer and 1 mL of prostaglandin screening antiserum were added. The plate was covered with a plastic film and transferred to the eye socket (Kunming mice) for incubation at room temperature for 18 hours. The wells were washed 6 times with a washing buffer containing 0.05% polysorbate-20, and the plate was cleared from the reaction. Ellman's reagent (200 mL) was then added to each well and incubated at room temperature for 60-90 minutes with shaking. The plate was recorded until the absorbance of the control well produced an OD value between 0.3 and 0.8 at 415 nm. The inhibition rate was calculated according to the following formula: Inhibition rate = (control group OD value - test group OD value) / control group OD value * 100%; IC was calculated by regression analysis (probit analysis, SPSS16.0) 50 The test results are shown in Table 2.
[0139] Table 2
[0140]
[0141]
[0142] As can be seen from Table 2, the pentacyclic triterpenoid compounds prepared in Examples 1-20 of the present invention exhibit good inhibitory activity on cyclooxygenase COX-2, and the effect is significantly better than indomethacin and resveratrol, which indicates that the pentacyclic triterpenoid compounds prepared in the present invention are suitable for preparing anti-inflammatory drugs or anti-inflammatory cosmetics.
[0143] Embodiment 21-40
[0144] The embodiment of the pentacyclic triterpenoid compound of the present invention, the preparation method of the pentacyclic triterpenoid compound comprises the following steps:
[0145] S1. At 0°C, 10 g of reactant A was dissolved in 80 mL of anhydrous dichloromethane, and 3 mL of triethylamine and reactant B were added in sequence, the molar ratio of reactant B to reactant A was 1:1, and the mixture was stirred at 0°C for 30 min; then the mixture was heated to room temperature (25°C) and kept at room temperature for 5 h; after the reaction was completed by thin layer detection, the organic solvent was evaporated under reduced pressure, and 50 mL of ethyl acetate and 50 mL of deionized water were added for extraction to obtain an organic phase, which was dried over anhydrous sodium sulfate, filtered, and concentrated to obtain a concentrate; reactant A and reactant B are shown in Table 3.
[0146] S2. The concentrate obtained in step S1 is subjected to silica gel column chromatography to obtain the pentacyclic triterpenoid compound, and the yield thereof is shown in Table 3, wherein the yield = (theoretical yield of the compound - actual yield of the compound) / theoretical yield of the compound.
[0147] The pentacyclic triterpenoid compounds obtained in the above Examples 21-40 were subjected to nuclear magnetic resonance detection.
[0148] The carbon spectrum and hydrogen spectrum detection showed that Examples 21-40 successfully prepared the following pentacyclic triterpenoid compounds:
[0149] Among them, -R 1 , -R 2 and-R 3 As shown in Table 3.
[0150] Table 3
[0151]
[0152]
[0153] Effect Example 2
[0154] In order to verify the efficacy of the pentacyclic triterpenoid compounds obtained in Examples 21-40 of the present invention, tests were performed according to the steps of Effect Example 1. The test results showed that the inhibition rate of the pentacyclic triterpenoid compounds obtained in Examples 21-40 on COX-2 was not less than 90%, and the IC 50 Not higher than 45μM.
[0155] Finally, it should be noted that the above embodiments are only used to illustrate the technical solution of the present invention rather than to limit the scope of protection of the present invention. Although the present invention has been described in detail with reference to the preferred embodiments, those skilled in the art should understand that the technical solution of the present invention can be modified or replaced by equivalents without departing from the essence and scope of the technical solution of the present invention.
Claims
1. A pentacyclic triterpenoid compound, characterized in that: Its structural formula is as follows: Wherein, R1 is an organic diacid monomethyl ester acyl group, R2 is -CH3 or -H, and R3 is -CH3 or -H.
2. The pentacyclic triterpenoid compound according to claim 1, characterized in that: The organic diacid monomethyl ester acyl group includes any one of malonic acid monomethyl ester acyl group, succinic acid monomethyl ester acyl group, fumaric acid monomethyl ester acyl group, maleic acid monomethyl ester acyl group, glutaric acid monomethyl ester acyl group, adipic acid monomethyl ester acyl group, suberic acid monomethyl ester acyl group, azelaic acid monomethyl ester acyl group, sebacic acid monomethyl ester acyl group, and dodecanedioic acid monomethyl ester acyl group.
3. A method for preparing a pentacyclic triterpenoid compound as claimed in any one of claims 1 to 2, characterized in that: The steps include: S1. In the presence of an organic solvent, a pentacyclic triterpenoid raw material and an organic diacid monomethyl ester or an organic diacid monomethyl ester chloride are stirred and reacted under the action of an organic amine to obtain a crude reaction product; S2, distilling the crude reaction product obtained in step S1 under reduced pressure to remove the organic solvent to obtain a concentrate; The pentacyclic triterpenoid raw material includes at least one of oleanolic acid and ursolic acid; S2. The concentrate obtained in step S2 is subjected to silica gel column chromatography to obtain the pentacyclic triterpenoid compound.
4. The method for preparing pentacyclic triterpenoid compounds according to claim 3, characterized in that: The molar ratio of the organic diacid monomethyl ester chloride to the pentacyclic triterpenoid raw material is (1-2):
1.
5. The method for preparing pentacyclic triterpenoid compounds according to claim 3, characterized in that: The organic diacid monomethyl chloride includes any one of malonic acid monomethyl chloride, succinic acid monomethyl chloride, fumaric acid monomethyl chloride, maleic acid monomethyl chloride, glutaric acid monomethyl chloride, adipic acid monomethyl chloride, suberic acid monomethyl chloride, azelaic acid monomethyl chloride, sebacic acid monomethyl chloride and dodecanedioic acid monomethyl chloride.
6. The method for preparing pentacyclic triterpenoid compounds as claimed in claim 3, characterized in that: Step S1 specifically comprises: dissolving an organic diacid monomethyl ester in an organic solvent at 0-5° C., then sequentially adding 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride and 1-hydroxybenzotriazole, and reacting with stirring for 20-40 minutes; adding a pentacyclic triterpene raw material and an organic amine to the reaction mixture at 0-5° C., and continuing to react with stirring for 3-8 hours to obtain a crude reaction product; The organic diacid monomethyl ester includes any one of monomethyl malonate, monomethyl succinate, monomethyl fumarate, monomethyl maleate, monomethyl glutarate, monomethyl adipate, monomethyl suberate, monomethyl azelaic acid, monomethyl sebacate, and monomethyl dodecanedioate.
7. The method for preparing pentacyclic triterpenoid compounds as claimed in claim 3, characterized in that: Step S1 specifically comprises: dissolving the pentacyclic triterpenoid raw material in an organic solvent at 0-5°C, adding an organic amine and an organic diacid monomethyl chloride in sequence, stirring for 20-40 minutes, heating to 16-26°C and stirring for 1-5 hours to obtain a crude reaction product.
8. Use of the pentacyclic triterpenoid compound according to any one of claims 1 to 2 in the preparation of anti-inflammatory drugs.
9. The use according to claim 8, characterized in that The dosage forms of the anti-inflammatory drug include tablets, granules and capsules.
10. Use of the pentacyclic triterpenoid compound according to any one of claims 1 to 2 in the preparation of anti-inflammatory cosmetics.
Citation Information
Patent Citations
Application of 11, 28-dihydroxy-oleanane-2, 12-diene in preparing medicine treating skin diseases
CN101756995A
Ursolic acid modifier polyol monoesters with anti-cancer activity
CN101928322A
Pentacyclic triterpenoid compounds, preparation method thereof, and application of compounds to prepare medicines controlling tumors
CN104530172A
Application of pentacyclic triterpenoids in treatment of neurodegenerative diseases
CN115246868A
Ramification of pentacycle triterpene, preparation method and application
CN1796401A
